Lafarge X
EFS Aquitaine Limousin, unité Inserm 1035, équipe cellules souches hématopoïétiques normales et leucémiques, place Amélie-Raba-Léon, CS 21010, 33075 Bordeaux cedex, France.
Transfus Clin Biol. 2017 Sep;24(3):124-130. doi: 10.1016/j.tracli.2017.06.006. Epub 2017 Jul 11.
The diversification of potential donors to perform stem cell allografts now enables to propose a compatible graft cell source adapted to the different clinical situations. Transplants with a geno-identical sibling donor, otherwise with the most HLA-compatible unrelated donor, remain the first-line solutions. Alternative transplants allow to graft patients having no donors in international registries, owing to the rarity of their HLA typing. They are carried out with fairly incompatible grafts and are therefore limited by the existence in the recipient of preformed anti-HLA antibodies which predispose to their rejection. The simple prevention of acute Graft-versus-host disease in haplo-identical transplants, as well as the availability of donors, explain why they have very often replaced placental stem cell transplants. These latter remain useful for pediatric patients or in the absence of family donors.
目前,用于进行干细胞同种异体移植的潜在供体的多样化使得能够提出适合不同临床情况的相容移植物细胞来源。与基因相同的同胞供体进行移植,否则与 HLA 相容性最高的无关供体进行移植,仍然是一线解决方案。替代性移植允许为国际登记处中没有供体的患者进行移植,这是由于他们 HLA 分型罕见所致。这些移植是用相容性相当低的移植物进行的,因此受到受者体内预先存在的抗 HLA 抗体的限制,这些抗体会导致移植物被排斥。单倍体相合移植中简单的急性移植物抗宿主病预防措施以及供体的可用性,解释了为什么它们经常取代胎盘干细胞移植。胎盘干细胞移植对儿科患者或在没有家庭供体的情况下仍然有用。